The lab of Yongchao C. Ma, PhD, at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago discovered a fundamental biological mechanism that could lead to new treatments for neurological diseases, such as spinal muscular atrophy (SMA) and autism, as well as different cancers. The study was published in the journal Human Molecular Genetics.

Dr. Ma's team found that chemical modification of RNA (called RNA methylation) regulates mitochondrial function.

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain.

Moderna Moves Cambridge Employees Into New Headquarters 4/4/2024

How to Manage Your Manager: Tips for Managing Up 4/4/2024

The Top 11 Companies Hiring in Biopharma Now 4/4/2024

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

The therapy, an antibody-drug conjugate (ADC), combines an antibody that targets a protein called TRBC1 expressed on the surface of T-cell cancers with an anti-cancer drug, called SG3249.

Changes in the gut microbiome have been implicated in a range of diseases including type 2 diabetes, obesity, and inflammatory bowel disease. Now, a team of researchers at the Broad Institute of MIT and Harvard along with Massachusetts General Hospital has found that microbes in the gut may affect cardiovascular disease as well. In a study published in Cell, the team has identified specific species of bacteria that consume cholesterol in the gut and may help lower cholesterol and heart disease risk in people.

Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.

The new technique, detailed in a preclinical study published in Nature Biomedical Engineering, involves combining chimeric antigen receptors (CAR) with mesenchymal stromal cells (MSC), resulting in engineered stem cells known as CAR-MSCs.

WuXi AppTec Shared Client IP with Beijing, Say US Intelligence Officials: Reuters 3/29/2024

BMS’ Zeposia Fails to Meet Primary Endpoint in Phase III Crohn’s Trial 3/29/2024

Gilead Wins Label Expansion for Vemlidy to Treat Hepatitis B Virus in Kids 3/29/2024

FDA Extends Review Period for Applied Therapeutics’ Govorestat by Three Months 3/29/2024

The IRA, Medicare and the High Costs of GLP-1 Drugs Like Wegovy 3/29/2024

What Lonza’s $1.2B Buy of Roche Biologics Plant Means for CDMO Market 3/29/2024

Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot 3/29/2024

Gamida Restructures Under Ownership of Highbridge Capital Management 3/29/2024

A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field of drug discovery. This innovative framework adeptly integrates structured and unstructured knowledge, enhancing the AI-driven exploration of molecular dynamics and interactions.

EU Approves Merck’s Keytruda, Chemo Combo for Lung Cancer 3/28/2024

Akebia’s CKD Anemia Drug Ends Tough Regulatory Path with FDA Approval 3/28/2024

Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of... 3/28/2024